A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

Recruiting

• Conditions: Hepatocholangiocarcinoma; Hepatic Epithelioid Hemangioendothelioma; Hepatoblastoma; Fibrolamellar Carcinoma; Hepatic Neuroendocrine Carcinoma; Hepatic Cystadenoma; Hepatic Leiomyosarcomas; Hepatic Angiosarcomas; Hepatic Carcinosarcomas; Cholangiocarcinoma

• Registration Number: NCT06541652
• Lead Sponsor: Federation Francophone de Cancerologie Digestive

Brief Summary

The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.

Detailed Description

The aim is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences.

Study Timeline

• Study Start: 2024-03-26
• Study First Submitted: 2024-07-15
• Study First Submitted QC: 2024-08-02
• Study First Posted: 2024-08-07
• Status Verified: 2025-02
• Last Update Submitted: 2025-08-04
• Last Update Posted: 2025-08-05
• Primary Completion: 2026-02
• Study Completion: 2031-02-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• 18 years of age or older,
• with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
• diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
• for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.

Exclusion Criteria

• without social security
• No access to tumor block

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers	up to 5 years from the date of diagnosis	Description of the clinical, histological and radiological characteristics of various rare primary liver cancers

Secondary Outcome Measures

Name	Time	Method
Recurrence-free survival (for non-metastatic patients)	up to 5 years from diagnosis	Time interval between the date of disease diagnosis and the date of locoregional and/or metastatic recurrence or death (all causes). Patients alive and without recurrence will be censored at the date of last news
Progression-free survival (for metastatic patients)	up to 5 years from diagnosis	Time interval between the date of diagnosis of the disease and the date of radiological and/or clinical progression or death (all causes). Patients alive and progression-free will be censored at the date of last news.
Overall survival	up to 5 years from diagnosis	Time interval between the date of diagnosis of the disease and the date of death (from all causes). Living patients will be censored at the date of last news.

Trial Locations

Locations (40)

CHU Amiens picardie; 🇫🇷 Amiens, France

Chu Angers; 🇫🇷 Angers, France

Ch - Centresimone Veil de Beauvais; 🇫🇷 Beauvais, France

Chu Jean Minjoz; 🇫🇷 Besançon, France

Ch Bethune Beuvry; 🇫🇷 Bethune, France

Avicenne; 🇫🇷 Bobigny, France

Cote de Nacre; 🇫🇷 Caen, France

Centre Hospitalier; 🇫🇷 Calais, France

Chu de Clichy Hopital Beaujon; 🇫🇷 Clichy, France

Centre Hospitalier Universitaire Henri Mondor; 🇫🇷 Creteil, France

Scroll for more (30 remaining)